Jazz Pharmaceuticals plc, Pfizer, Inc. and Eli Lilly and Company are Dominating the Global Sleep Disorder Treatment Market in 2020

Global Sleep Disorder Treatment Market is expected to grow with the CAGR of 8.4% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-sleep-disorder-treatment-market

Global sleep disorder treatment market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global sleep disorder treatment market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio. For instance, In January 2018, Aurobindo Pharma USA received the U.S. FDA approval for its generic drug named Armodafinil Tablets, 50 mg, 150 mg, and 250 mg for treating sleep apnea and narcolepsy. This new drug approved by the company has strengthened its sleep disorder portfolio leading to increased sales and demand in future.

Jazz Pharmaceuticals plc is the dominating player in global sleep disorder treatment market. The other key players existing in the market includes Pfizer Inc., Viatris Inc., Arbor Pharmaceuticals, Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma), sanofi-aventis U.S. LLC (a subsidiary of Sanofi), Hikma Pharmaceuticals PLC , Amneal Pharmaceuticals LLC., Lupin Pharmaceuticals, Inc. (a subsidiary of Lupin), Taj Pharmaceuticals Limited, Eli Lilly and Company, Mallinckrodt, Alembic Pharmaceuticals Limited, Apotex Inc., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Taro Pharmaceutical Industries Ltd., Koninklijke Philips N.V., DeVilbiss Healthcare LLC, ResMed , SomnoMed, Oventus and BMC Medical Co.

Sleep Disorder Treatment MarketJazz Pharmaceuticals plc:

Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland. The company is engaged in the developing life-changing medicines for people with serious or rare diseases having limited or no treatment options in order to make them live a better life. The company is providing products under sleep therapeutic area and hematology/oncology therapeutic area product categories. The market focus products lie under sleep therapeutic area product category. The company is engaged in continuous development of sleep disorder treatment.

  • In September 2020, Jazz Pharmaceuticals plc announced the collaboration with American Heart Association's sleep health educational content in order to strengthen its sleep heath therapeutic area. This new collaboration done by the company has increased its credibility in the market.

The company has wide presence across Asia-Pacific, Europe, Middle East and Africa, North America and South America. The company has various subsidiaries like Jazz Pharmaceuticals Ireland Limited (Ireland), Gentium S.R.L. (Italy), Jazz Pharmaceuticals France SAS (France), Celator Pharmaceuticals, Inc. (U.S.) and Jazz Capital Limited (Ireland) among more.

Pfizer, Inc.

Pfizer, Inc. is headquartered in New York, U.S. was founded in 1849. The company is focused on providing standard for quality, safety and value in the discovery, development and manufacturing of health care products, including innovative medicines and vaccines. The company has multiple business segments such as biopharma, upjohn and consumer health in which biopharma is the market focused segment. The company is providing products under BeneFIX, Besponsa, Bosulif, Celebrex, Chantix, Cutaquig, Daurismo, Duavee, Effexor XR, Elelyso, Eliquis, Estring, Eucrisa, Flector, Gel-Flow Kit, Gel-Flow NT, Ibrance, Inflectra, Inlyta, Lipitor, Lorbrena, Lyrica, Mylotarg, Nivestym, Nyvepria, Octagam 10%, Panzyga, Premarin, Prevnar, Pristiq, Relpax, Retacrit, Revatio, Ruxience, Somavert, Sutent, Talzenna, Tikosyn, Torisel, Toviaz, TRAZIMERA, Trumenba, Viagra, Vizimpro, Vyndamax, Vyndaqel, Xalkori, Xeljanz, Xtandi, Xyntha Antihemophilic Factor, Xyntha Solofuse Antihemophilic Factor, Zirabev, Zoloft, Sonata CIV (Zaleplon). The market focus products lie under Effexor XR, Pristiq, Sonata CIV (Zaleplon) product category. The company is engaged in continuous development of sleep disorder treatment.

  • In November 2019, Pfizer, Inc. announced that its division named Upjohn is combined with Mylan N.V. and formed a new company named Viatris. This combination of the business division of the company with Mylan N.V. has increased its product portfolio leading to increased demand for its product in the market.

The company has wide presence across Europe, North America, South America, Asia-Pacific and Middle East and Africa. The company also has various subsidiary companies such as Pfizer Animal Health B.V. (Netherlands), Pfizer Asia International B.V.(Netherlands), Pfizer Australia Superannuation Pty Ltd ( Australia), Pfizer Dominicana, S.A.(Dominican Republic) and Pfizer Egypt S.A.E.(Egypt) among others.

Eli Lilly and Company:

Eli Lilly and Company was founded in 1876, and is headquartered in Indiana, the U.S. The company is engaged in production and trading of high-quality medicines for which come under the human pharmaceutical products. The company is engaged in providing products in categories such as historic medicines, current medicines among which historic medicines is the market focused category.

For instance-

  • In April 2007, Eli Lilly and Company announced Hypnion, Inc.; a private company specialized in sleep disorder research. This acquisition done by the company has strengthened its neuroscience business segment leading to increased revenue in the future.

The company has wide presence across Europe, North America, South America, and Asia-Pacific. The company has various subsidiary companies such as Alnara Pharmaceuticals, Inc. (U.S.), AME Torreview LLC (U.S.), Andean Technical Operations Center (Peru), Dista-Produtos Quimicos & Farmaceuticos, LDA (Portugal) and E L Management LLC (U.S.) among others. The company has initiated many strategic initiatives to expand its market.